These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8396956)
21. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Keeling DM; Richards EM; Baglin TP Br J Haematol; 1994 Feb; 86(2):425-6. PubMed ID: 7515270 [TBL] [Abstract][Full Text] [Related]
22. Suitability of low-molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model. Lozano M; Bos A; de Groot PG; van Willigen G; Meuleman DG; Ordinas A; Sixma JJ Arterioscler Thromb; 1994 Jul; 14(7):1215-22. PubMed ID: 8018678 [TBL] [Abstract][Full Text] [Related]
24. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354 [TBL] [Abstract][Full Text] [Related]
25. Determination of low molecular weight heparin in clinical laboratory. van Putten J; van de Ruit M; Beunis M; Hemker HC Haemostasis; 1984; 14(2):205-10. PubMed ID: 6203817 [TBL] [Abstract][Full Text] [Related]
26. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665 [TBL] [Abstract][Full Text] [Related]
27. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma. Zammit A; Dawes J Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481 [TBL] [Abstract][Full Text] [Related]
29. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Hobbelen PM; Vogel GM; Meuleman DG Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660 [TBL] [Abstract][Full Text] [Related]
30. Orgaran in the prevention of deep vein thrombosis in stroke patients. Turpie AG Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
32. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462 [TBL] [Abstract][Full Text] [Related]
33. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats. Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330 [TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711 [TBL] [Abstract][Full Text] [Related]
35. Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol. Stiekema JC; de Boer A; Danhof M; Kroon C; Broekmans AW; van Dinther TG; Voerman J; Breimer DD Haemostasis; 1990; 20(3):136-46. PubMed ID: 1696921 [TBL] [Abstract][Full Text] [Related]
36. Normal and low molecular weight heparins: interaction with human platelets. Fabris F; Fussi F; Casonato A; Visentin L; Randi M; Smith MR; Girolami A Eur J Clin Invest; 1983 Apr; 13(2):135-9. PubMed ID: 6223824 [TBL] [Abstract][Full Text] [Related]
37. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Norrheim L; Abildgaard U; Larsen ML; Lindahl AK Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967 [TBL] [Abstract][Full Text] [Related]
38. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Ofosu FA; Smith LM; Anvari N; Blajchman MA Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191 [TBL] [Abstract][Full Text] [Related]
39. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Vun CM; Evans S; Chong BH Thromb Res; 1996 Mar; 81(5):525-32. PubMed ID: 8907311 [TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]